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Economic Evaluation
Long-Term Cost-Effectiveness of Smoking Cessation Interventions in
People With Mental Disorders: A Dynamic Decision Analytical Model
Qi Wu, MSc, Simon Gilbody, PhD, Jinshuo Li, MPhil, Han-I Wang, PhD, Steve Parrott, MSc
A B S T R A C T
Objectives: People with mental disorders are more likely to smoke than the general population. The objective of this study is
to develop a decision analytical model that estimates long-term cost-effectiveness of smoking cessation interventions in this
population.
Methods: A series of Markov models were constructed to estimate average lifetime smoking-attributable inpatient cost and
expected quality-adjusted life-years. The model parameters were estimated using a variety of data sources. The model
incorporated uncertainty through probabilistic sensitivity analysis using Monte Carlo simulations. It also generated tables
presenting incremental cost-effectiveness ratios of the proposed interventions with varying incremental costs and
incremental quit rates. We used data from 2 published trials to demonstrate the model’s ability to make projections
beyond the observational time frame.
Results: The average smoker’s smoking-attributable inpatient cost was 3 times higher and health utility was 5% lower than ex-
smokers. The intervention in the trial with a statistically insignificant difference in quit rate (19% vs 25%; P=.2) showed a 45%
to 49% chance of being cost-effective compared with the control at willingness-to-pay thresholds of £20 000 to £30 000/
quality-adjusted life-years. The second trial had a significant outcome (quit rate 35.9% vs 15.6%; P,.001), and the
corresponding probability of the intervention being cost-effective was 65%.
Conclusions: This model provides a consistent platform for clinical trials to estimate the potential lifetime cost-effectiveness of
smoking cessation interventions for people with mental disorders and could help commissioners direct resources to the most
cost-effective programs. However, direct comparisons of results between trials must be interpreted with caution owing to
their different designs and settings.
Keywords: decision analytical model, long-term cost-effectiveness, mental disorders, smoking cessation.
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Introduction
Tobacco smoking remains the leading preventable cause of
morbidity and mortality worldwide.1 In the United Kingdom,
although the prevalence of smoking in the general population fell
from 45% in 1975 to 15% in 2018,2 smoking rates remain much
higher among individuals with mental disorders (MDs): condi-
tions that affect mood, thoughts, and behavior.3,4 In 2014,
approximately 1 in 6 adults in England was classed as having a
common MD (CMD), which includes various types of depression,
and 34% of them were smokers.5,6 For those with severe MDs
(SMDs), the smoking rate may exceed 50%.4,5 SMD here refers to
serious psychological conditions that may cause insight and
cognitive impairments, including bipolar disorder, schizophrenia
and affective psychosis, and other non-organic psychotic
disorders.5
People with MDs are more likely to smoke than the general
population and are also likely to smoke more heavily.4,7 Despite
their high levels of nicotine dependence, evidence suggests that
the proportion of people with MDs who want to quit smoking is
similar to that of the general population. Data from the Health
Survey for England 2012 show that 69% of smokers taking psy-
choactive medications would like to quit smoking compared with
66% of those in the general population.4 Nevertheless, their
smoking cessation rate remains much lower.8 High tobacco con-
sumption and low quit rates can put smokers with MDs at a higher
risk of developing smoking-related diseases (SRDs) and conse-
quently constitute a significant economic burden (an estimated
£719 million in 2009-2010) to the National Health Service
(NHS).4,9
Many interventions are available to help people stop smoking,
including pharmacotherapies (nicotine replacement therapy, var-
enicline, bupropion, and e-cigarette), intensive behavioral sup-
port, and combination therapies. Such smoking cessation
interventions have proven to be highly cost-effective in both the
short term and long term for the general population.10
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Nevertheless, people with MDs are often actively excluded from
clinical trials; consequently, evidence on the effectiveness and
cost-effectiveness of smoking cessation interventions among this
population is relatively scarce.11,12 Although some clinical trials
have assessed the short-term cost-effectiveness of smoking
cessation interventions in people with MDs, very few studies have
considered the long-term cost-effectiveness of these in-
terventions.13-16 Within-trial cost-effectiveness analysis may fail
to capture the full benefit of smoking cessation interventions,
because the main benefits of quitting are improved health and
healthcare cost saving that come from the reduced risks of
developing SRDs in the long run.17,18
The aim of this article was to develop an adaptable and flexible
decision model that facilitates comparisons of the long-term cost-




The model was designed to reflect the complexities and
adaptability of the long-term impacts of smoking status on the
costs of SRDs and quality-adjusted life-years (QALYs) in people
with various MDs. A schematic representation of the model is
shown in Figure 1.
The model first allows users to select a category of MD related
to their clinical trial.
Here, we included 17 widely studied MDs based on data from
the 2014 Adult Psychiatric Morbidity Survey (APMS).4,5 These 17
MDs covered the majority of the MDs identified in APMS where
participants’ mental health and smoking status were both re-
ported.5 For each MD, a Markov model was constructed to
estimate lifetime smoking-attributable costs (SACs) and QALYs for
patients with that particular MD; patients with multiple MDs
were not included in this model.
This model includes people with MDs aged 35 years and more
because evidence suggests that people who quit smoking before
the age of 35 years are no more likely to experience negative
health consequences than people who have never smoked.19,20
Meanwhile, the published relative risks of developing SRDs for
smokers and ex-smokers used to project long-term outcomes
were only available for people older than 35 years.21
The Markov models for the 17 MDs have the same 3-state
structure: current smokers, ex-smokers, and death. For each
intervention arm, the trial cohort enters the Markov model as
current and ex-smokers according to the cessation rate, based on
trial observations. Smokers and ex-smokers could transit to other
states or remain in the same state at the end of each 1-year cycle,
whereas the death state absorbs those who died within the cycle.
Each state is associated with an annual smoking-attributable
healthcare cost and a health outcome in terms of annual QALYs
at the end of each cycle. The model runs until everyone dies or
reaches the age of 90 years, which was considered to be a lifetime.
SACs and QALYs are then summed up over all cycles separately to
generate lifetime SACs and lifetime QALYs for each trial inter-
vention, and the results of the interventions are compared.
Further modeling details are described in the Model Inputs
section. For simplicity, it is assumed that once a cohort enters the
model, participants will receive no further smoking cessation in-
terventions. The model was programmed in Microsoft Excel 2016
(Microsoft Corporation, Redmond, WA, www.microsoft.com).
Model Inputs
The model parameters were measured separately and stratified
by age, gender, smoking status, and MDs whenever the data were































Obsessive compulsive disorder (OCD)
Panic disorder
Mixed anxiety/depression
Post-traumatic stress disorder (PTSD)
Psychotic disorder (past year)
Personality disorder
Eating disorder
Attention deficit hyperactivity disorder
Bipolar disorder
Harmful drinking and alcohol dependence
Dependent on cannabis
Dependent on any other drug
Suicidal thoughts (past year)
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available to accommodate all modeled cohorts. The same layout
was used in the results tables reporting prevalence, costs, and
QALYs. Further details can be found in the Appendix Tables (in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.04.002) and are available from the authors upon request.
Transition probabilities
In the absence of evidence of the overall relapse rate in people
with MDs, we employed a 10% annual relapse rate for 10 years
after quitting and assumed no subsequent relapse after the 10th
year, based on published systematic reviews and surveys in the
general population.22-24 Because smokers might quit smoking
without a cessation aid, an annual background or spontaneous
abstinence rate of 4.1% was taken into account.25
Annual mortality rates were calculated by applying relevant
weights to the mortality rates of the general population. First, the
annual all-cause mortality rates were estimated by age and gender
using data from deaths registered in England and Wales in 2017.26
Second, to adjust for the impact of smoking, the increased relative
risks of mortality for smokers and ex-smokers were derived from
the British doctors’ study, which had a 50-year follow-up, and
applied to the all-cause mortality rates.18 Finally, to reflect that
people with MDs have a higher risk of death than the general
population, smoking-adjusted mortality rates were further
multiplied by the increased relative risks of the 17 MDs, which
were estimated based on data from various sources.27-38 The pa-
rameters for transition probabilities applied in the model are
summarized in Table 1.
Prevalence of MDs and smoking
The prevalence of MDs and smoking were used to estimate the
SACs incurred by people with different MDs. The prevalence of the
17 MDs was extracted from the 2014 APMS (Appendix 1 in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2021.
04.002).5 For age groups where data regarding the prevalence of
MD was unavailable, data from the adjacent lower age group were
used instead. Owing to the lack of detailed information in the
literature on smoking status in people with MDs, patient-level
Table 1. Summary of the transition probabilities applied in the model.
Parameters Value (SE) Source
Quit rate – Based on the trials
Probability of relapse (first 10 years) 10.00% (3.06%) 22–24
Background cessation rate 4.1% (0.77%) 25
Discount rate 3.50% (0) 45
Mortality
Age group Mortality: males, smokers (SE) Mortality: males, ex-smokers (SE) 18,26
16-24 0.040% (0.000%) 0.040% (0.000%)
25-34 0.070% (0.000%) 0.070% (0.000%)
35-44 0.236% (0.001%) 0.175% (0.001%)
45-54 0.811% (0.001%) 0.515% (0.003%)
55-64 1.898% (0.004%) 1.215% (0.006%)
65-74 5.070% (0.015%) 3.030% (0.014%)
751 25.516% (0.173%) 15.214% (0.117%)
Age group Mortality: females, smokers (SE) Mortality: females, ex-smokers (SE)
16-24 0.020% (0.000%) 0.020% (0.000%)
25-34 0.035% (0.000%) 0.035% (0.000%)
35-44 0.152% (0.000%) 0.113% (0.000%)
45-54 0.528% (0.001%) 0.335% (0.002%)
55-64 1.236% (0.003%) 0.791% (0.004%)
65-74 3.339% (0.010%) 1.996% (0.010%)
751 21.154% (0.142%) 12.613% (0.096%)
Relative risks of mortality for the 17 mental disorders
Mental disorder Relative risk of mortality compared with people without the condition
(SE)
Generalized anxiety disorder 1.61 (0.11) 27
Depression 1.52 (0.04) 28
Phobias 1.61 (0.11) 27
OCD 1.88 (0.36) 29
Panic disorder 1.61 (0.11) 27
Mixed anxiety/depression 1.61 (0.11) 27
PTSD 2.10 (0.23) 30
Psychotic disorder (in the past year) 2.60 (0.03) 31
Personality disorder (males) 5.00 (0.13) 32
Eating disorder 1.92 (0.27) 33
ADHD 2.07 (0.20) 34
Bipolar disorder 2.60 (0.03) 31
Harmful drinking and alcohol
dependence
3.45 (0.27) 35
Dependence on cannabis 0.95 (0.07) 36
Dependence on any other drug 1.27 (0.13) 36
Suicidal thoughts (past year) 1.23 (0.03) 37
Suicide attempts (past year) 3.60 (0.08) 38
ADHD indicates attention-deficit/hyperactivity disorder; OCD, obsessive-compulsive disorder; PTSD, posttraumatic stress disorder; SE, standard error.
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data from the latest wave of the APMS (2014) were requested
through the UK Data Service (http://ukdataservice.ac.uk).19 The
APMS data classified participants as current smokers, ex-smokers,
and never-smokers. The proportion of smoking status was sum-
marized by participants’ MDs and can be found in Appendix 2 (in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.04.002).
SACs
The model allows the intervention and healthcare costs during
the trial period to be input as a one-off cost. The annual healthcare
costs over the projection period are prespecified by MD, smoking
status, age group, and gender. In the Markov model, we used
smoking-attributable hospital admissions costs as an approxima-
tion of additional healthcare costs for current smokers and ex-
smokers compared with never-smokers. All model costs were
expressed in British pounds and inflated to 2018 to 2019 year where
necessary using the Hospital and Community Health Services Pay
and Prices Inflation Index for costs incurred before 2016 and the
NHS Cost Inflation Index for costs incurred in 2016 or later.39
Annual SAC was calculated following the cost-of-illness
approach introduced by the World Health Organization Eco-
nomics of Tobacco Toolkit.40 Equation 1 shows the formula used to
calculate SAC. A total of 52 SRDs were included in the costing.
These diseases were selected based on the 2018 Royal College of
Physicians report wherein the authors summarized the relative
risks of developing these SRDs for smokers or ex-smokers
compared with never-smokers (Appendix 3 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.04.002).21












SACmsga denotes SACs for people with MD “m,” smoking status “s,”
gender “g,” and age group “a”; pmsga denotes the prevalence of
smoking status “s” in people with MD “m,” gender “g,” and age
group “a”; rris denotes the relative risk of SRD “i” in people of
smoking status “s” compared with the general population;
THQmsgai denotes the number of annual hospital admissions for
SRD “i” for people with MD “m,” gender “g,” and age group “a”;
and UCi denotes the unit cost per hospital episode of SRD “i.”
For each SRD, the number of annual hospital admissions was
extracted from the Hospital Episode Statistics41 for 2015 to 2016
by gender and age group. It was then multiplied by the smoking-
attributable proportion of the same characteristics to calculate the
number of smoking-attributable hospital admissions for each SRD
in this group.
The set of unit costs per hospital episode for the SRDs was
derived from the NHS reference cost and matched to the Hospital
Episode Statistics data through the HRG41 code to group
workbook.21,42,43
The SACs of the SRDs were then calculated by multiplying unit
costs by their respective numbers of smoking-attributable hospital
admissions. For people with the same MD, smoking status, age
group, and gender, the inpatient SACs of 52 SRDs were summed up
to produce an estimated annual SAC.
QALYs
QALY is a generic measure of health benefit that combines both
the quality and quantity of life lived.44 It is the preferred health
outcome measure for economic evaluations recommended by
many guidelines including the National Institute for Health and
Care Excellence guide to methods of technology appraisal in the
United Kingdom.45
QALYs are calculated based on health utility. Health utility is a
summary score that assesses the value of various health statuses
as measured by instruments such as EQ-5D, Health Utilities Index
Mark 3, or SF-6D.44 In the absence of published health utilities for
people with MD, we estimated utility scores for this population
using data extracted from the APMS 2007 study.46 The APMS 2007
was the most recent wave of APMS surveys that collected data on
patients’ smoking status alongside their health status using the
12-item Short Form Health Survey (SF-12) questionnaire.
Following the methods proposed by Brazier et al,47-49 the reported
SF-12 data were converted to the SF-6D utility score, where 1
represents perfect health, 0 represents death, and negative
numbers represent states worse than death. Given the purpose of
this study, the APMS SF-12 data used to calculate utility scores
were restricted to people with MDs.
The utility scores at each time point were then used to
generate QALYs using the area under the curve approach.50 For age
groups where utility scores were unavailable for certain MDs in
the APMS data, the average score for the same age group was used
instead. Both future costs and health outcomes were discounted at
an annual rate of 3.5%.45
Cost-Effectiveness Analysis and Probabilistic Sensitivity
Analysis
The model conducts an incremental cost-effectiveness analysis
comparing the lifetime SACs and QALYs of the smoking cessation
interventions described in clinical trials. Model inputs require a
range of trial data, including demographic information such as the
MD of the target population, number of participating smokers,
mean age, and gender composition of each intervention arm. The
intervention-related variables include quit rates, mean interven-
tion costs with standard error (SE), and mean QALYs with SE over
the trial period.
If all required information is available, incremental cost-
effectiveness ratios (ICERs) are calculated by dividing the differ-
ence in expected SACs by difference in expected QALYs between
interventions. The ICERs can then be compared with the selected
decision-making willingness-to-pay (WTP) threshold. The anal-
ysis takes the perspective of the NHS and personal social services
over a lifetime horizon.
To assess uncertainty in parameter estimates, the model runs a
probabilistic sensitivity analysis (PSA) using Markov chain Monte
Carlo simulations. Appropriate distributions were selected from
which random values for model parameters were drawn. A beta
distribution was assigned for probabilities and a gamma distri-
bution was assigned for QALYs and costs.51 A cost-effectiveness
plane and cost-effectiveness acceptability curve, along with a
summary message, are then generated based on the 10 000 Monte
Carlo iterations.52
ICER Tables
Compared with smoking cessation intervention trials in the
general population, the number of smoking cessation intervention
trials focused on people with MDs is relatively small, and most
such trials have not reported the costs and the QALYs of the in-
terventions.11-13 In the absence of within-trial costs and QALYs for
the existing trials or before the implementation of a new trial, the
model also allows researchers and decision makers to assess the
lifetime cost-effectiveness of the interventions, by generating a
table to present the ICERs of the proposed interventions with
varying hypothetical incremental costs and incremental quit rates
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for a specified subgroup of smokers by conducting a 2-way
sensitivity analysis.
Application to Published Trial Data
For illustrative purposes, we used empirical data from pub-
lished clinical trials as model inputs to demonstrate the model’s
analyses. Two randomized controlled trials (RCTs) were chosen
based on the most recent published systematic review of smoking
cessation interventions for smokers with depression, one of the
most prevalent MDs.53
The first trial, conducted by Hall et al,54 was the only trial to
have published a cost-effectiveness article wherein intervention
costs were reported.14 This trial included 322 participants and
examined the efficacy of a staged care intervention compared with
a brief contact control. The quit rates at the end of the 18-month
follow-up were estimated at 19.1% for the control group and 24.6%
for the intervention group (P = .2). The reported intervention costs,
converted to 2018 to 2019 pounds sterling, were £3748 (SE £440)
for the control and £4316 (SE £392) for the intervention.
The second trial, conducted by Anthenelli et al,55 had the
largest sample size (525 smokers) of all RCTs in the review. It
compared varenicline with a placebo. The carbon monoxide (CO)–
confirmed continuous abstinence quit rate at 3 months was
significantly higher in the varenicline group than in the placebo
group (35.9% vs 15.6%; P , .001). This trial did not report any cost
information; we estimated the average cost of the intervention (1
mg varenicline, twice daily for 12 weeks) at £163.80 per partici-
pant using data from the 2019 NHS prescription cost analysis.56
Neither trial reported any QALY-related outcomes; we assumed
that the 2 groups in each trial were well balanced in terms of
quality of life after randomization and thus that the incremental
Table 2. Model inputs and outputs based on RCTs by Hall and Anthenelli.54-56
Trial Group types
Hall’s RCT Control group Intervention group
Brief contact control Staged care intervention
Model inputs
Number of smokers 159 163
Mean age 42 42
Gender (male, %) 29% 32%
Quit rate at 18 mo 19% 25%
Mean total cost (18 mo) £3748 £4316
SE of the mean cost £440 £392
QALYs – –
SE of mean QALYs – –
Model outputs
Intervention BC Intervention SCC
Mean lifetime SAC £4951 £5523
Mean lifetime QALY gains 12.547 12.564
Lifetime ICER £33744/QALY
Probability be cost-effective at WTP threshold
£20000 55% 45%
£30000 51% 49%
Anthenelli’s RCT Control group Intervention group
Placebo Varenicline
Model inputs
Number of smokers 269 256
Mean age 47 45
Gender (male, %) 37% 38%
Quit rate at 3 mo 16% 36%
Mean intervention cost (3 mo) £0 £164
SE of the mean cost £0 £0
QALYs – –
SE of mean QALYs – –
Model outputs
Placebo Varenicline
Mean lifetime SAC £1446 £1563
Mean lifetime QALY gains 9.817 9.856
Lifetime ICER £3002/QALY
Probability be cost-effective at WTP threshold
£20000 35% 65%
£30000 35% 65%
BC indicates brief contact; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; RCT, randomized controlled trial; SAC, smoking-attributable cost;
SCC, staged care intervention; SE, standard error; WTP, willingness to pay.
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QALYs between groups within the trial periods were considered to
be negligible owing to the limited follow-up period. Further de-
tails about the information extracted from the published trials and
used to inform the model are presented in Table 2.
Results
Costs and QALYs
Based on the APMS 2014 data, the results show that smoking was
about twice as prevalent among people with a CMD (31%) than
among those without a diagnosis (17%) (Appendix 4 A in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2021.04.002).
The smoking rate was approximately 3 to 4 times higher among
those with SMDs than those without (Appendix 4 B in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.04.002). For
example, smoking prevalence was 75% versus 17% respectively in
peoplewith andwithout drug dependence, 60% versus 19% in people
with and without alcohol dependence, and 53% versus 19% in people
with and without schizophrenia and bipolar disorders.
Appendix 5 (in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.04.002) summarizes the mean annual
SACs per person for people with 1 of the 17 selected MDs. SACs
increased with age and varied by MD. SACs were substantially
higher for smokers than ex-smokers and were highest among
male smokers (£368). Generally, men had higher SACs than
women within the same age group. SACs among male smokers
and male ex-smokers ranged from £26 to £368 and £7 to £135,
respectively, whereas in women, it was estimated at £21 to £305
for smokers and £5 to £100 for ex-smokers.
Appendix 6 (in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.04.002) presents the mean utility scores
for people with MDs by age, gender, and smoking status. Among
people with MDs, the utility scores of ex-smokers were 0.03 to
0.05 higher than those who continued to smoke. This is equivalent
to an average 5% increase in health utility gained from quitting
smoking. The estimated utility scores were 0.02 to 0.04 higher for
men than women in the same age and MD group. In general,
health utility decreased with age; nevertheless, the scores for age
groups 45 to 54 years and 55 to 64 years were very close.
Cost-Effectiveness Analysis Results of Selected RCTs
Both trial-based model inputs and cost-effectiveness analysis
results from the model for the 2 selected trials are outlined in
Table 2. For the trial by Hall et al54, the expected lifetime SAC and
QALYgains per personwere £4951 versus £5523 and 12.547 versus
12.564 for the brief contact and staged care interventions,
respectively. The ICER of the intervention compared with the
control was £33 744 per QALY. The results of the PSA for the trial
by Hall et al54 are displayed in Figure 2. In the cost-effectiveness
plane, the ICER iterations were scattered across 4 quadrants. The
cost-effectiveness acceptability curve showed that the probability
of the staged care being more cost-effective than brief contact was
45% to 49% at the WTP threshold range of £20 000 to £30 000 per
QALY.
Meanwhile, smokers from the study by Anthenelli et al55
who received varenicline gained an average of 0.039 more
QALYs than those who received the placebo, at an increased
cost of about £117, yielding a lifetime ICER of £3002 per QALY.
The results of the PSA (Fig. 3) indicate that varenicline’s
chance of being more cost-effective than placebo remained at
65% through the WTP threshold range of £20 000 to £30 000/
QALY.
Assuming both trial-related costs and quit rates data were
unavailable, Table 3 presents an example of ICER tables for the
cohort of patients from the trial by Hall et al.54 The potential
lifetime ICERs were estimated using different combinations of
incremental quit rate (ie, the quit rate in the intervention group
minus the quit rate in the control group) and incremental cost (ie,
the mean cost in the intervention group minus the mean cost in
the control group). For example, if the expected incremental quit
rate was 10%, using a WTP threshold of £20 000 per QALY, the
intervention cost should be kept below £500 per person to ensure
that the new intervention is more cost-effective than the control
at a lifetime horizon. In contrast, if the trial has a budget of £500
per capita, an additional 10% or more incremental quit rate is
required to ensure the new intervention’s long-term cost-effec-
tiveness. Appendix 7 (in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2021.04.002) shows a more complete ICER
table based on the cohorts from both Hall’s and Anthenelli’s
studies.
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Discussion
The objective of this study was to construct a dynamic de-
cision analytical model to assess the lifetime cost-effectiveness
of smoking cessation interventions for people with various
MDs. To the best of our knowledge, this is the first study of its
kind to model the long-term cost-effectiveness of smoking
cessation interventions in this population. The ability to make
long-term prediction is important in evaluating smoking
cessation programs because the benefits of quitting smoking do
not always show immediately within the time frames of trials.
Not considering the long-term benefits of quitting smoking,
especially its impact on the risk of developing SRDs, may lead
to erroneous conclusions about some potentially cost-effective
interventions. Constructing models to predict the long-term
economic and health impacts of each individual trial is
impractical. Our model allows predefined trial cohorts to be
projected and, therefore, provides a platform for timely and
consistent comparison of smoking cessation programs. This
model focuses on the cost-effectiveness of the studied trial in-
terventions, so it is assumed that after the end of the trial
period, participants received no further smoking cessation
interventions.
Our results show that compared with people without MDs,
smoking was twice as prevalent in people with CMDs and that
smoking rate could reach as high as 75% for those with SMDs. This
finding is consistent with those in the literature that people with
MDs are more likely to smoke than the general population.4
Compared with ex-smokers, the healthcare SACs of people who
continued to smoke were 3 times higher and their health utility
was 5% lower. This indicates that smoking cessation may yield
substantial cost savings and improved health-related quality of life
for this vulnerable group. The result shows that the utility scores
of ex-smokers were 0.03 to 0.05 higher than those of current
smokers among people with MDs, a trend that is similar to the
difference between ex-smokers and current smokers found in the
general population in the literature.57,58 Although the model was
demonstrated using data from England, it may be adapted for use
in other countries where local data are available. For example,
local SACs (calculated by multiplying the total health expenditure
by smoking attribution proportion) and local QALYs may be used
as model inputs to generate country-specific estimates for the
interventions.
We used data from 2 published RCTs to demonstrate the
model’s ability to make projections beyond the observational time
frame and assess the impact of smoking cessation interventions


























Table 3. ICER table for the cohort from Hall’s trial.
Incremental quit rate (intervention – control) Incremental cost (intervention – control)
£100 £300 £500 £700 £900
1% £13 160 £36953 £60745 £84537 £108330
10% £3809 £11687 £19565 £27443 £35322
25% £1368 £5093 £8819 £12544 £16269
50% £344 £2327 £4310 £6293 £8277
75% -£27 £1324 £2675 £4026 £5378
100% 2£219 £806 £1830 £2855 £3880
Note. This table presents the potential lifetime ICERs for given combinations of incremental quit rate in the first column (ie, the quit rate in the intervention group minus
the quit rate in the control group) and incremental cost in the third row (ie, the mean cost in the intervention group minus the mean cost in the control group). For
example, if we look at the fourth row and fourth column, a new intervention with an expected incremental quit rate of 10% and incremental cost of £500 has an
ICER of £19565 compared with the control intervention.
ICER indicates incremental cost-effectiveness ratio.
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well into the future. The model provided lifetime SAC and QALY
gains for all trial interventions. ICERs were generated and
compared with the selected WTP thresholds to establish cost-
effectiveness. The model also quantified the uncertainty around
the results using PSA where all parameters were simultaneously
varied over chosen distributions. Other 1-way or 2-way sensitivity
analyses to test the impact of individual parameters are also
possible.
The PSA reflects the effects of the within-trial outcomes. For
example, the difference in quit rate between the 2 arms of Hall’s
trial was statistically insignificant (19% vs 25%; P = .2); the PSA
results showed that the probability that the intervention was cost-
effective was approximately 50%, indicating a high level of
uncertainty, and hence, the results should be interpreted with
caution. By contrast, in Anthenelli’s trial, a significant outcome
(35.9% vs 15.6%; P , .001) led to more certain long-term results.
Nevertheless, the direct comparisons of results between trials
must be interpreted with caution owing to the difference in
outcome measures. For example, the trial by Hall et al54 used a 7-
day abstinence from cigarettes, verified by expired air CO at #10
ppm to define abstinence from smoking, whereas the study by
Anthenelli et al55 employed a CO-validated continuous abstinence
rate for the last 4 weeks.
In the absence of within-trial costs and QALYs, the model can
also produce ICER tables for any target population with MDs. For
heavily dependent smokers, such as people with MDs, more
intensive levels of cessation interventions are required, and thus,
trials could be expensive to run. The ICER table provides a useful
tool to inform planning and budgeting for future trials.
Another strength of this model is the number of SRDs it con-
siders. Few previous studies have considered SRDs in their models,
and among those that have, only a small number of key SRDs such
as lung cancer, chronic obstructive pulmonary disease, and coro-
nary heart disease have been included.59-61 This model, in
contrast, includes a wider range of 52 diseases associated with
smoking, allowing both smoking- and MD-related morbidity and
mortality to be adjusted simultaneously for long-term outcomes.
Hence, the generated predictions are better able to capture the
real costs and QALYs associated with MDs and smoking status
than previous models.
Impact of Model Assumptions
The limitations of the model are mostly related to the as-
sumptions made in its development. First, owing to the model
structure design and the availability of evidence, this model only
allows evaluations of interventions targeting smokers with a
single MD. Such restriction is likely to exclude a good portion of
study population, as approximately 30% of the participants iden-
tified with MD met the criteria for at least 2 different MDs based
on the APMS 2007 survey.46 The assumption that participants only
have 1 MD at a time may lead to an underestimation of partici-
pants’ SACs and overestimation of their QALYs. Nevertheless, this
impact should be balanced across the 2 trial arms after random-
ization and should not affect the comparative cost-effectiveness of
the 2 interventions.
Second, the SAC in this model covers costs incurred in inpa-
tient settings only. Other types of primary care and community-
based care were not included owing to data constraints. The
assumption that primary care costs have the same distribution as
hospital admissions costs may lead to an underestimation of SACs
for people who continue to smoke. For instance, many SRDs are
chronic conditions that are likely to be treated in outpatient set-
tings. Nevertheless, it is unclear to what extent this assumption
affects the predicted costs.
Another limitation is the comparability of QALY results. The
QALYs used in this model were calculated from SF-6D instead of
the more widely used EQ-5D owing to the limited availability of
data for people with MDs. Therefore, any direct comparison
between our model results and results based on EQ-5D in other
studies should be made with caution. The limitations of the
model, such as the lack of multiple MDs and primary care data
in people with MDs, identified a gap in the literature and po-
tential areas for future research. Updated models will be
required to explore this gap once additional data become
available.
Conclusions
People with MDs are more likely to smoke than the general
population and are also likely to smoke more heavily. The pre-
sented model permits the comparison of the long-term cost-
effectiveness of different programs to help people with MDs quit
smoking. The model enables the consideration of lifetime SACs
and health gains using the most recent evidence and provides
useful information about what interventions should be commis-
sioned to decision makers. However, the model’s assumptions and
local population characteristics should be examined carefully
before applying the model to specific studies, and direct com-
parisons of results between trials must be interpreted with
caution owing to their different designs and settings.
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